Neumentum, a pharmaceutical company dedicated to transforming the way acute and chronic pain are treated – without opioids – today announced that it has raised $6 million in a Series A funding round through the sale of Series A Convertible Preferred Stock. Brookline Capital Markets acted as the exclusive placement agent for the financing.